View Clinical Trial (Medical Research Study)

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI) - NCT00951210-27710(Clinical Trial 304532)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Durham
State:  
NC
Zip Code: 27710
Conditions: Peripheral Artery Disease - Peripheral Vascular Disease - Critical Limb Ischemia
Purpose: The purpose of this study is to determine the safety of PLX-PAD, Intra-muscular injections for the treatment of CLI patients.
Study summary:
Criteria: Inclusion Criteria: 1. Diagnosis of critical limb ischemia defined as persistent, recurring ischemic rest pain for at least two (2) weeks, and/or ulceration or gangrene of the foot or toe, with ABI < 0.6 or/and TBI < 0.4 2. Rutherford category 4-5 3. Non candidate for revascularization or endovascular intervention based on unfavorable vascular anatomy or significant co-morbid medical conditions as confirmed by vascular study (e.g., angiogram, MRA) obtained within 3 months prior screening visit and signed approval of vascular surgeon. The decision to classify the subject as a non-candidate will be made by the investigator and confirmed by an independent third party vascular surgeon who is not participating in the study. 4. In the opinion of the investigator, major amputation is not anticipated over a period of three (3) months. 5. Those diabetic subjects who are on optimal diabetes medication, with an HbA1c < 8% Exclusion Criteria: 1. Uncontrolled hypertension (defined as diastolic blood pressure > 110 mmHg or systolic blood pressure > 180 mmHg during screening). 2. Wounds with severity greater than Grade 2 on the Wagner Scale 3. Life-threatening ventricular arrhythmia - except if an ICD is implanted - or unstable angina - characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged. 4. ST segment elevation myocardial infarction and/or TIA/CVA within six (6) months prior to enrollment.Patients with severe congestive heart failure (i.e. NYHA Stage IV) 5. In the opinion of the investigator, the patient is unsuitable for cellular therapy.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: November 28, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.